Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Clostridium difficile and Clostridium perfringens research, Microscopic Colitis, Gut microbiota and health, and Gastrointestinal motility and disorders.
Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients
Responsible use of large language models in gastroenterology and hepatology.
Clostridioides difficile infection in inflammatory bowel disease: an observational study in flares of ulcerative colitis and a South Asian region-specific systematic review and meta-analysis.
Fecal microbiota transplantation in chronic liver disease: Current and future state of the art.
Machine Learning Model Predicts Recurrent Clostridioides difficile Infection in Patients With Inflammatory Bowel Disease (Recur CDI-IBD).
Risk Factors and Management of Incomplete Microscopic Colitis: A Systematic Review and Meta-Analysis.
Microbiota-Based Therapies for Clostridioides difficile
AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review
Reporting guideline for the use of Generative Artificial intelligence tools in MEdical Research: the GAMER Statement
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.
Utilizing large language models for gastroenterology research: a conceptual framework.
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA<sup>®</sup>) administered by colonoscopy for prevention of recurrent <i>Clostridioides difficile</i> infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial.
The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.
Body mass index changes after fecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection.
Patient-reported benefits of colonoscopicallyadministered microbiota restoration therapy: a qualitative study of adult patients with recurrent <i>Clostridioides difficile</i> infection.
Real-world use of bezlotoxumab to prevent recurrent <i>Clostridioides difficile</i> infections: a single-center experience and meta-analysis.
Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection.
Effects of Oral Anticoagulant and Antiplatelet Agents on Performance of Multitarget Colorectal Cancer Screening Test
International consensus statement on microbiome testing in clinical practice
Evolving Landscape of Large Language Models: An Evaluation of ChatGPT and Bard in Answering Patient Queries on Colonoscopy
Artificial Intelligence–Powered Patient Education for Comprehensive and Individualized Understanding for Patients
Sex-Discordant Fecal Microbiota Transplantation for Clostridioides difficile May Increase Risk of Postinfection Irritable Bowel Syndrome
Effectiveness of Bile Acid Sequestrants in Microscopic Colitis and Utility of Bile Acid Testing: A Systematic Review and Meta-analysis.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Integrating Clinical Guidelines With ChatGPT-4 Enhances Its’ Skills
Rise to the Challenge: Master the Management of Clostridioides difficile Infection
Fecal microbiota live - jslm (Rebyota™/RBL) for management of recurrent <i>Clostridioides difficile</i> infection.
Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent <i>Clostridioides difficile</i> infection.
Durability and outcomes of fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with moderate to severe inflammatory bowel disease.
Patient Education: Hepatitis C Infection